Alterity Therapeutics Limited (ATHE:NASDAQ) closed at $2.62 on October 16, 2026, down 2.60% on the day. The stock trades 55.5% below its 52-week high of $5.89 and 11.5% above its 52-week low of $2.35. Over the past year, it lost 46.4%. Alterity Therapeutics Limited is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -10.58% | -30.13% | -44.73% | -49.13% | -46.42% |
In 252 trading sessions since October 16, 2025, ATHE closed higher on 104 days (41%). Its best day was April 20, 2026 (+15.21%) and its worst was May 15, 2026 (-13.70%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.
Prana Biotechnology Ltd is active in the healthcare domain. The company is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing.
Find more stocks like ATHE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.